SuperX
  1. Home
  2. Stocks
  3. LIVEN

LIVEN Liven Pharma share price

Liven Pharma in one paragraph

As of 20 Nov 2026, the Liven Pharma (LIVEN) share price is Rs 52.40 (+9.99% on the day). Over the last year it has moved +1.12%. Its market capitalisation is about Rs 5.9B. PSX lists it as Shariah-compliant. Liven Pharma is in the Pharmaceuticals sector.

Close · 20 Nov 2026 · Pakistan Stock Exchange · Vol 3.5M

Rs 52.40

+4.76 (+9.99%)

Chart LIVEN in SuperX Apex

52-week low27.82

52-week high63.48

Daily closes from the Pakistan Stock Exchange, to 20 Nov 2026.
LIVEN · close, 20 Nov 2025 to 20 Nov 2026 249 sessions

Rs 52.40 20 Nov 2026 · +1.12% since 20 Nov 2025

20 Nov 2025 H 61.91 · 27 Nov 2025 L 28.85 · 3 Mar 2026 20 Nov 2026

RResults filedNo marks before 25 Nov 2025: SuperX's dated record of dividends and results starts there.

A period starts at the last close on or before the same date one week, one, three or six months, or one, three or five years earlier, and ends at the latest close drawn. The year to date starts at the last close of the previous year.

1 week
+33.71%
1 month
+66.61%
3 months
+50.57%
6 months
+45.23%
Year to date
+0.83%
1 year
+1.12%
3 years
+269.27%
5 years
+171.78%
Since Sep 2016
+863.24%

Daily closes from the Pakistan Stock Exchange, to 20 Nov 2026.

Last price
Rs 52.40
20 Nov 2026
Change on the day
+9.99%
+Rs 4.76
Market cap

Market cap

What the whole company costs at today's price.

How it's worked out

Share price multiplied by every share in issue.

How to read it

It is the company's size, not its value. A big number does not mean the price is high against earnings, and a small one does not mean it is low — that is what the ratios below are for.

Rs 5.9B
as of 20 Nov 2026
Price per rupee earned

Price per rupee earned

Rupees you pay for each rupee the company earned last year.

How it's worked out

Share price divided by earnings per share over the last twelve reported months.

How to read it

Lower only means something against something — the same company's history, its sector, or the market. On its own this ratio says very little, and it is blank when a company lost money.

—
Dividend yield

Dividend yield

Cash paid out over the last year as a percentage of today's price.

How it's worked out

Dividends per share over twelve months divided by the share price.

How to read it

A very high yield is often a warning, not a gift: it usually means the price fell. Check the payout ratio next to see whether earnings actually cover it.

—
Earnings per share
Rs -0.07
twelve months to 30 Sep 2026
52-week range
27.82 – 63.48
the price is at 69% of the range
Day range
45.05 – 52.40
prev close 47.64
Volume
3.5M
shares, this session
Avg volume (30d)

Average volume

Shares changing hands on a typical day.

How it's worked out

The mean daily volume over thirty sessions.

How to read it

Shares, not rupees — a million shares of a Rs 3 stock is a small market. "Traded per session" is the version in money.

326K
7 more figures
Beta vs KSE-100

Beta

How hard it swings when the market swings.

How it's worked out

The slope of this stock's daily returns against the KSE-100's, over a year of sessions.

How to read it

1.0 moves with the market, 1.5 exaggerates it by half, below 1 is steadier. It says nothing about direction, only about size.

1.12
1 year of daily closes
Shares outstanding

Shares outstanding

Every share the company has issued.

How it's worked out

The share count in the company's own filings, including the blocks nobody trades.

How to read it

Divide any per-share figure by this. It is larger than the free float on almost every PSX name, because sponsors and the government own shares that never reach the market.

113M
Free float

Free float

The shares that can actually be bought and sold.

How it's worked out

Total shares minus the blocks held by sponsors, the government and other locked-in holders, as the exchange reports them.

How to read it

The float, not the market cap, is what sets how easily a real position can be built or unwound.

11.3M
10% of shares
Last results filed
5 Oct 2026
Index member
All-Share, KMI All-Share
Shariah
Compliant

Figures as of 20 Nov 2026.

What changed for LIVEN

Latest · to 20 Nov

  • 20 NovClosed 52.40, +9.99%. Volume 3.53 m, 11.2 times the average of the 30 sessions before it, 315,586.
  • 2 NovResults filed on 2 Nov 2026; the figures are not stored yet. All results
  • 17 NovTrend read changed to leaning up: above the 50-day average; up 54.9% over 3 months; fell 53.4% from its 1-year peak at worst.

Closes and notices: PSX. Trend read: SuperX, from daily closes. Volume: against the average of the 30 sessions before the last. Not advice.

What SuperX wrote about LIVEN

SuperX holds no shares in Liven Pharma.

  1. No filing, story or sector move explains it. The price rose 9.99% on 20 Nov.

  2. The volume was 3.53 million shares, 5.74 times the usual volume. Only 9 of 248 sessions moved as far.

  3. Latest results show EPS of -0.07, against -0.28 a year ago. The price fell 6 times after results since 17 Mar 2025.

Written by SuperX’s analyst desk from SuperX’s own figures, from the close of 20 Nov 2026. Each number was checked against those figures. Not advice.

01Returns1 year +1.12%

LIVEN in figures

As of 20 Nov 2026. Each figure states its period, its basis and its source. Not advice.

Return over time

Returns to the price at 16:45 on 20 Nov 2026. The sector median runs to the close of 20 Nov 2026, over 14 companies.

Change in price since 21 Nov 2025, weekly closes, each line starting at zero

Price only, weekly closes, 21 Nov 2025 to 20 Nov 2026.
MethodEvery line starts at 0% on 21 Nov 2025. The index line is the KSE-100 price index (KSE100PR), which leaves dividends out, so both lines are price only. The table below gives the return with dividends. Source: PSX closes and the KSE100PR index.

Return with dividends over each window, against the KSE-100

Return with dividends, not reinvested. The windows of a group share one scale; the two groups do not. Source: PSX closes and payout notices.
OverPrice onlyWith dividendsKSE-100Sector median
1 monthfrom the close of 20 Oct 2026, Rs 31.45+66.61%+66.61%+7.41%+4.09% (10 companies)
3 monthsfrom the close of 20 Aug 2026, Rs 34.80+50.57%+50.57%+0.45%−3.06% (10 companies)
6 monthsfrom the close of 20 May 2026, Rs 36.08+45.23%+45.23%+7.61%−1.83% (10 companies)
Since 1 Januaryfrom the close of 31 Dec 2025, Rs 51.97+0.83%+0.83%+1.91%−10.71% (10 companies)
1 yearfrom the close of 20 Nov 2025, Rs 51.82+1.12%+1.12%+8.87%−14.10% (10 companies)
3 yearsfrom the close of 17 Oct 2023, Rs 14.19+269.27%+269.27%+210.77%+130.02% (9 companies)
5 yearsfrom the close of 19 Nov 2021, Rs 19.28+171.78%+171.78%+281.55%+54.75% (9 companies)

Price only: closes adjusted for bonus and rights issues, to the latest price. With dividends: adds cash dividends, not reinvested. The KSE-100 figure reinvests dividends. Source: PSX closes and payout notices.

02ValueAgainst the sector

Key figures against the sector

Against sector and market

Each group has its own scale. Medians count only companies with the figure (yield: payers). "Above": share of other listed companies lower.
Dividend yield0.00%8 of 14 sector companies pay a dividendCash dividends of the last 12 months over the price
Net profit as a share of sales-29.43%sector median 10.57% (13 companies) · 378.4% below the sector median · above 0 of 13 sector companiesLatest filed year, to 30 Jun 2026, company accounts
Move with the KSE-100 (beta), 1 year1.12sector median 1.01 (14 companies) · 11.1% above the sector median · above 11 of 14 sector companiesDaily price changes over the year to 20 Nov 2026, against the KSE-100
Return over 1 year, with dividends1.12%sector median -10.59% (14 companies) · 2.1 times the sector median · above 11 of 14 sector companiesPrice change over one year plus cash dividends, not reinvested
Gross profit as a share of sales25.18%Latest filed year, company accounts

A figure is called above or below the sector median when the gap is more than 10%.

Compared with the 14 other companies in its PSX sector, Pharmaceuticals. A sector median is left out when no other company in the sector has the figure (for the dividend yield, none that pays).

The same ratio on other definitions

LIVEN earnings per share: Rs -0.07 · unconsolidated · twelve months to 30 Sep 2026 · PSX company page

The valuation in context

How does LIVEN’s valuation compare with its sector?

From filed accounts and LIVEN's price history · as of 20 Nov 2026

One ratio on its own says little. These put LIVEN's valuation next to its sector and the market, its dividend next to its earnings, its quoted price next to how much of it actually trades, and its return next to the risk taken to earn it.

Valuation in context

Earnings yield

Earnings yield

What the business earns on its price, so it lines up with a savings rate.

How it's worked out

Earnings per share divided by the share price — the price-to-earnings ratio turned over.

How to read it

If a company earns 17% against its price and a T-bill pays 12%, you can finally compare the two. It is what the business earns, not what it pays you — the dividend yield is the cash that reaches your account.

—
Price to sales

Price to sales

What you pay for each rupee of revenue.

How it's worked out

Market cap divided by the latest reported annual sales.

How to read it

Useful where earnings are negative or lumpy and a price-to-earnings ratio says nothing. It ignores costs entirely, so a low number does not mean a good business.

55.98×
Price, earnings and growth together

Price, earnings and growth together

The price per rupee earned, measured against how fast earnings are growing.

How it's worked out

The price-to-earnings ratio divided by the three-year growth rate of earnings per share.

How to read it

Under 1 is the old rule of thumb for a multiple that growth justifies. Blank when earnings are shrinking, because the ratio flips sign and stops meaning anything.

—
vs the KSE-100's own multiple

vs the KSE-100's own multiple

Whether a rupee of this company's earnings costs more or less than the market's.

How it's worked out

Its price-to-earnings ratio against the KSE-100's, which we compute as the total market cap of the index over the total earnings of its members.

How to read it

−30% means it trades thirty percent below the market's multiple. Below the market is a question, not an answer: often the market is right about why.

—
vs KSE-100, one year

vs KSE-100, one year

How far ahead of or behind the market it finished.

How it's worked out

Its one-year return minus the KSE-100's, in percentage points.

How to read it

"Up 12%" means one thing when the index rose 20% and another when it fell. Unlike alpha, this ignores how much market risk was carried to get there.

-1.3 pts

Income & quality

Dividend per share, 12 months

Dividend per share

The actual rupees per share paid out over the last twelve months.

How it's worked out

Every cash dividend with an ex-date in the last year, added up from the exchange's own book-closure notices.

How to read it

Multiply by your shares and that is the cash that reached you, before tax. Bonus shares are not in here — they are not money.

—
Cash dividends paid, 12 months

Dividends paid

How many times it paid cash in the last twelve months.

How it's worked out

A count of cash dividends with an ex-date in the last year.

How to read it

Four usually means a quarterly payer, one means an annual one. A steady cadence is worth more to an income investor than a single big number.

—
Payout ratio

Payout ratio

How much of its profit the company hands to shareholders.

How it's worked out

Dividend per share over the last year divided by earnings per share.

How to read it

Above 100% means it paid out more than it earned — possible from reserves for a year, not for five. Low means it is keeping money to reinvest, which is not automatically bad.

—
Dividend cover

Dividend cover

How many times over the earnings could pay the dividend.

How it's worked out

Earnings per share divided by dividend per share — the payout ratio the other way round.

How to read it

Above 2 is comfortable. Below 1 means the dividend is coming from somewhere other than this year's profit.

—
Net margin

Net margin

How much of every rupee of sales survives to profit.

How it's worked out

Net profit after tax divided by sales, from the annual filing.

How to read it

Compare it only within an industry — a supermarket at 3% can be healthier than a manufacturer at 10%. The direction matters more than the level.

-29.4%
Margin, 3-year change

Margin, 3-year change

Whether the business is getting more or less profitable.

How it's worked out

The latest net margin minus the one three years earlier, in percentage points.

How to read it

A widening margin on flat sales is a company with pricing power. A shrinking one is usually costs, competition, or both.

—
EPS growth, 3-year

EPS growth, 3-year

How fast profit per share has compounded.

How it's worked out

The annual rate that turns the earnings per share of three years ago into today's.

How to read it

Blank if the company was losing money three years ago — a move from a loss to a profit has no meaningful growth rate, and printing one would be arithmetic pretending to be insight.

—
Sales growth, 3-year

Sales growth, 3-year

How fast revenue has compounded.

How it's worked out

The annual rate that turns the sales of three years ago into today's.

How to read it

Read it next to EPS growth. Sales rising faster than profit means the growth is being bought with margin.

—

Can you actually trade it

Median traded per session

Traded per session

The rupees that change hands on a typical day.

How it's worked out

The median of price times volume over the last 60 sessions — the median, so one block trade cannot make a dead stock look busy.

How to read it

This is the number that decides whether the quoted price is a price you can actually get.

Rs 690K
Sessions to trade Rs 1M

Sessions to trade Rs 1M

How long it would take to trade into or out of a Rs 1,000,000 position.

How it's worked out

Rs 1,000,000 divided by the median rupees traded a session.

How to read it

Under 0.01 and your order is a rounding error. Above 1 and you are the day's volume — expect to move the price against yourself getting out.

1.45
Untraded sessions, last 60

Untraded sessions

Days in the last 60 when literally nothing traded.

How it's worked out

A count of sessions with zero volume.

How to read it

Any number above zero means there are days you could not have sold at any price. On PSX this is common well outside the KSE-100.

0
Daily volume vs free float

Daily volume vs free float

What share of the tradable stock changes hands on a normal day.

How it's worked out

Average daily volume divided by the free float — the shares not locked up by sponsors.

How to read it

A company can be huge and still barely trade if the family owns 90% of it. This separates size from liquidity.

5.43%
Price impact per Rs 1M traded

Price impact per Rs 1M

How much a Rs 1,000,000 order moves the price on a typical day.

How it's worked out

We take the size of the price move on each day and divide it by the money traded that day, then scale it to a Rs 1,000,000 order. We use the middle value over the last year. Traders call this the Amihud ratio. It is shown in basis points: 100 basis points is 1%, so 0.07 basis points is 0.0007%.

How to read it

A small number means an order of this size barely moves the price. A large number means the price moves a lot when someone buys or sells this much.

93 bps
Implied bid-ask spread

Implied bid-ask spread

The hidden cost of a round trip, estimated from the price series.

How it's worked out

Roll's estimator: prices bounce between bid and ask, and the size of that bounce implies the spread.

How to read it

It is the toll you pay to enter and leave, before any brokerage. Blank when the price is trending rather than bouncing, because then the model does not apply and we would rather say nothing.

—
Float turned over, one year

Float turned over, one year

How many times the tradable stock changed hands in a year.

How it's worked out

A year's volume divided by the free float. Exchanges publish this about themselves; this is the same measure for one company.

How to read it

100% means the entire float turned over once. Single digits mean a register that never moves, whatever the market cap says.

406%
Sessions with a trade, one year

Sessions with a trade

How often it trades at all.

How it's worked out

The share of the last 250 sessions with any volume.

How to read it

Anything below 100% means there were days with no market. Below 90% is more than 25 such days in the last 250 — on each of those days no trade happened at any price, so an order placed that day did not execute.

100%

Liquidity is thin: a Rs 1,000,000 order is about 145% of a normal session's turnover.

A Rs 1,000,000 ticket moves the price — about 93 basis points on the median session.

What the risk paid

Total return, one year

Total return, one year

What a holder actually made, dividends included.

How it's worked out

The price move over twelve months plus every cash dividend paid in that window, counted as received on its ex-date.

How to read it

Every other PSX site quotes the price move alone. On a market yielding what this one does, that understates what holders made by a third or more.

+1.1%
— from the price
+1.1%
— from dividends

— from dividends

The part of the year's return that arrived as cash.

How it's worked out

Dividends per share over the year divided by the price twelve months ago.

How to read it

The half of the return a price chart cannot show you. For many PSX names it is most of it.

—
Return per unit of risk

Return per unit of risk

How much you were paid for how rough the ride was.

How it's worked out

The one-year return divided by the annualised volatility of the daily moves.

How to read it

Two stocks up 20% are not the same if one did it calmly and the other halved on the way. Deliberately not a Sharpe ratio: quoting a risk-free rate for Pakistan means picking a T-bill tenor and pretending that was your alternative.

0.02
Alpha vs KSE-100, one year

Alpha vs KSE-100

The part of the year's return the market does not explain.

How it's worked out

The stock's return minus its beta times the index's return.

How to read it

A high-beta name rising in a rising market has done nothing clever. This strips that out and leaves what was actually the company's doing.

-1.6 pts
Caught of the market's up moves

Caught of the market's up moves

How much of the market's good days this stock catches.

How it's worked out

The stock's total return across the index's up days, divided by the index's own.

How to read it

Above 100 means it rises more than the market does. Read it with down capture — the pair is the whole picture, either half alone flatters.

111%
Caught of its down moves

Caught of its down moves

How much of the market's bad days this stock catches.

How it's worked out

The stock's total return across the index's down days, divided by the index's own.

How to read it

Below 100 means it falls less than the market. Above 100 means it falls further than the market does on the market's bad days, which a headline return usually hides.

109%
Worst day in twenty

Worst day in twenty

The fall to expect on a bad day.

How it's worked out

The fifth-percentile daily return over the last year — the actual distribution, not a bell curve.

How to read it

One session in twenty is at least this bad. It is a normal day at the office, not a crash, and the crash is worse than this by definition.

−5.8%
Below its 52-week high

Below its 52-week high

How far under its best price of the year it sits now.

How it's worked out

The 52-week high minus today's price, as a percentage of that high.

How to read it

Different from the biggest drawdown, which is the worst it ever got. This is the hole still to climb out of.

17.4% · 243 sessions

It has risen more than the index on its good days and fallen less on its bad ones.

Brokers’ price targets

Brokers’ 12-month price targets for LIVEN, not SuperX’s

Collected from sell-side research notes. The figures here are the brokers’.

No broker covers LIVEN in our records. Brokers cover 49 PSX companies and rate 47 of them buy.

Computed value range

No range: the company made a loss over the 12 months, so a price-to-earnings ratio has no meaning.

SuperX’s own method, worked out from the exchange’s ratios. It is not a broker’s target and not advice.

03Grades and checksGrades A to F

Grades, A to F

As of 20 Nov 2026. Each grade ranks LIVEN among 408 traded companies (at least Rs 10 m traded on 18 of the last 20 sessions), across the whole market and not only its sector. A: the top 20%. B: 60 to 80. C: 40 to 60. D: 20 to 40. F: the bottom 20%. The figures in a grade count equally.

Grade ranks, 0 to 100

Scale 0 to 100: the share of graded companies this one is ahead of.
MethodThe letter is the grade. The sector median is over 14 companies. The inputs are listed below.
Price against earnings, book value and dividend—

no grade: too few figures · from 1 of 3 figures

  • dividend yield: 0.00%, ahead of 28% of companies
Growth in sales and earnings—

no grade: too few figures · from 0 of 2 figures

Profit margin and return on equityF

ahead of 7.8% of graded companies · from 1 of 2 figures

  • net profit as a share of sales: -29.43%, ahead of 8% of companies
Price change over 90 days, 182 days and 1 yearA

ahead of 85.0% of graded companies · from 3 of 3 figures

  • return, 90 days: 54.89%, ahead of 95% of companies
  • return, 182 days: 45.92%, ahead of 85% of companies
  • return, 1 year: 1.12%, ahead of 58% of companies

Each letter shows where the company’s own figures stand among the traded companies on that date. Not advice and not a forecast.

04ResultsBy year and by quarter
Sales, profit and earnings per share, by year

What are LIVEN’s sales, profit and earnings per share?

Results, by period end

Earnings per share by financial year, Rs, with the change on the year before

Earnings per share, Rs, by year to the month shown; in brackets, the change on the year before (none where no year before is filed).
MethodA faded bar is a year whose share count no split or bonus issue explains: it is left out of growth.

Sales by financial year, Rs billion

Sales, Rs billion.

Profit margins by financial year

Share of sales, by year.
PeriodEarnings per share (Rs)SalesNet profit as a share of salesChange in earnings per share on the year before
Year to 30 Jun 2026-0.28Rs 105.8 m-29.43%—
Year to 30 Jun 2025-7.11left out of growth: the number of shares changed and no split or bonus issue explains itRs 127.3 m-459.22%—
Year to 30 Jun 20241.04left out of growth: the number of shares changed and no split or bonus issue explains itRs 245.1 m17.03%—
Year to 30 Jun 2023-1.02left out of growth: the number of shares changed and no split or bonus issue explains it———
Year to 30 Jun 2022-1.18left out of growth: the number of shares changed and no split or bonus issue explains it———

Sales and profit after tax by quarter, Rs billion

Sales and profit after tax by quarter, Rs bn.
MethodA blank is a quarter not filed separately. The fourth quarter is filed only inside the annual accounts.
QuarterEarnings per share (Rs)SalesProfit after taxChange on the same quarter a year before
Quarter to 30 Sep 2026-0.07Rs 14.3 mRs -7.4 m—
Quarter to 31 Mar 2026-0.03Rs 29.2 mRs -4.0 m—
Quarter to 31 Dec 2025-0.30Rs 54.6 mRs 28.2 m—
Quarter to 30 Sep 2025-0.28Rs 8.8 mRs -30.2 m—
Quarter to 31 Mar 2025-0.10Rs 14.8 mRs -9.6 m—

Company accounts as filed. Earnings per share are on today’s share count where a split or bonus issue came later. Years to 30 June. 5 years and 5 of the last 8 quarters.

Next results

Quarterly results, to 30 Sep 2026: expected between 14 Oct 2026 and 13 Nov 2026.

A projection, not an announced date. An estimate from the usual timing across the market; this company has no earlier filings on record.

Annual figures from the accounts filed with PSX. Amounts in rupees; earnings per share (EPS) in rupees a share.

Statements in SuperX Apex

FY (June) 2026202520242023
Sales Rs 106MRs 127MRs 245M—
Profit after Taxation −Rs 31.1M−Rs 584MRs 41.7M−Rs 12.3M
EPS Rs -0.28Rs -7.11Rs 1.04Rs -1.02
EPS Growth +96.1%−781.0%+202.3%+13.6%
Gross Profit Margin 25.2%14.1%25.5%—
Net Profit Margin −29.4%−459.2%17.0%—
When the next results are due

When the next results are due

A window from past filings, not a date

Period that closed
30 Sep 2026quarterly results
Expected between
14 Oct 2026 and 13 Nov 2026
Longest it has taken before
44 days
Filings the window rests on
0
Last results announced
5 Oct 2026

The window has passed and no results for this period are announced yet. It is built from 0 earlier filings, so a short record makes a wide window. Liven Pharma has announced no date.

Results filed across the exchange

05AccountsCash, debt and the balance sheet
06DividendsEvery payout
Every payout

LIVEN dividends and corporate actions

PSX quotes payouts as a % of the Rs 10 face value — 25% = Rs 2.50 per share. Unconfirmed ex-dates are marked “expected”.

Payouts in SuperX Apex

LIVEN dividends and corporate actions
Type % of face Per share Ex-date Book closure Qualify by
No dividends or corporate actions on record for LIVEN.
07Peers6 companies
Peers table

Other Pharmaceuticals stocks on PSX

Other companies in the same PSX sector, including its largest.

Against the largest companies in its sector

Net profit as a share of sales

Price change over 1 year

Market value, Rs billion

Market value, Rs billion, and its share of the 6 companies shown.

The company and the largest 5 others in its sector by market value, as of 20 Nov 2026. Sources: PSX prices and filed accounts.

LIVEN sector peers
Symbol Company Price Chg % Mkt cap Price/earnings
MACTER Macter International Limited 49.67 +1.68% Rs 11.4B 3.5×
OTSU Otsuka Pakistan Limited 448.14 −1.42% Rs 5.4B 11.1×
SAPL Sanofi-Aventis Pakistan Limited 870.00 0.00% Rs 8.4B
GLAXO GlaxoSmithKline Pakistan Limited 332.02 −0.92% Rs 106B 9.6×
ABOT Abbott Laboratories (Pakistan) Limited 1,013.28 +0.42% Rs 99.2B 10.7×
HALEON Haleon Pakistan Limited 687.73 0.00% Rs 80.5B 12.3×

5 of 6 companies shown have a price-to-earnings ratio in Pharmaceuticals; a blank cell means a loss or no ratio. Each ratio is the one printed on that company’s own page, to 20 Nov 2026.

All Pharmaceuticals stocks on PSX

08Price position69% of the 52-week range

Where the price stands

Closing price over one year

One close every two weeks to 20 Nov 2026, closes adjusted for splits and bonus issues.
MethodThe 52-week low 27.82 and high 63.48 are intraday highs and lows, set 3 Mar 2026 and 27 Nov 2025. Source: PSX closes.

Closing price over the last 20 sessions

Last 20 sessions, 23 Oct 2026 to 20 Nov 2026, closes adjusted for splits and bonus issues. Source: PSX closes.

Levels where the price turned most often in the last 12 months, one below and one above the close on 20 Nov 2026. A turn is a daily high or low that is the highest or lowest of the 5 sessions before it and the 5 after it; turns close together count as one level. Each line runs from its first turn to its last and stops there. Prices from 21 Nov 2025 to 20 Nov 2026, 248 sessions, adjusted for splits and bonus issues. Source: PSX daily prices.

  • Rs 34.40, below the close on 20 Nov 2026: 6 turns, the first on 30 Apr 2026 and the last on 19 Oct 2026.
  • Rs 55.14, above the close on 20 Nov 2026: 2 turns, the first on 2 Jan 2026 and the last on 10 Feb 2026.

Dated events on the one-year chart, 20 Nov 2025 to 20 Nov 2026, newest first: R results filed, D ex-dividend, B bonus issue, S split, T dealing by a director or major owner. Marked: dividend, bonus and split dates in the window, the latest results filing and the latest dealings. A number marks that many events too close together to draw apart. Sources: the company’s notices to PSX and the exchange’s payout records.

  • R 5 Oct 2026 · Results filed: Full-year results, to 30 Jun 2026
  • T 15 Jun 2026 · Dealing by a director or major owner: Sale, 10,000 shares
  • T 17 Apr 2026 · Dealing by a director or major owner: Sale, 32,001 shares
  • T 6 Mar 2026 · Dealing by a director or major owner: Purchase, 2,000 shares
  • T 6 Mar 2026 · Dealing by a director or major owner: Purchase, 2,000 shares
  • T 6 Mar 2026 · Dealing by a director or major owner: Purchase, 500 shares
  • T 6 Mar 2026 · Dealing by a director or major owner: Purchase, 500 shares
  • T 6 Mar 2026 · Dealing by a director or major owner: Purchase, 1,000 shares
  • T 6 Mar 2026 · Dealing by a director or major owner: Purchase, 1,000 shares
  • T 5 Mar 2026 · Dealing by a director or major owner: Purchase, 5,000 shares
  • T 4 Mar 2026 · Dealing by a director or major owner: Purchase, 10,000 shares

Place in the 52-week range

0% is the low and 100% the high of the last 52 weeks, as of 20 Nov 2026. Other companies: the largest in the same sector.
Place in the 52-week range
68.9% of the way from the low to the highintraday highs and lows, as of 20 Nov 2026

Reading of the last 14 days, weeks and months

Scale 0 to 100. Below 30 and above 70 mark the two outer bands. 14 completed days, weeks and months. Source: PSX closes.
Reading of the last 14 sessions
77.3 on a scale of 0 to 100, above 70session of 20 Nov 2026; below 30 and above 70 mark the two outer bands
Week reading, 14 weeks
74.9 on a scale of 0 to 100week to 20 Nov 2026; close Rs 52.40, above the average of the last 10 weekly closes, Rs 33.96
Month reading, 14 months
50.2 on a scale of 0 to 100month to 30 Oct 2026; close Rs 30.59, below the average of the last 10 monthly closes, Rs 35.57

Trend strength, 14 sessions

14 daily sessions, scale 0 to 100. Source: PSX highs, lows and closes.
Trend strength, 14 sessions
36.1 on a scale of 0 to 100over 14 daily sessions
Volume
3.53 m, 11.2 times the average of the 30 sessions before it, 315,586Average of the 30 sessions before the last.

PSX daily closes, as of 20 Nov 2026.

Trend and technical readings

Trend read

Leaning Up

Since 17 Nov 2026 · daily closes to 20 Nov 2026

  • •Above the 50-day average
  • •Up 54.9% over 3 months
  • •Fell 53.4% from its 1-year peak at worst
Stretched — recent buying ran hotHeavy trading volumeDeep drawdownHigh volatility

A description of the price series — moving averages, momentum, the 52-week position — held for three closes before it changes. It is a label, not advice. How it works

Buying vs selling, 14 sessions

Buying vs selling, 14 sessions

Whether recent buying or selling has run hot.

How it's worked out

Fourteen sessions of gains weighed against losses, on a 0–100 scale.

How to read it

Above 70 is called overbought and below 30 oversold. A share that keeps rising can sit above 70 for months, so this describes what the price has done; it does not forecast a turn.

77
stretched
vs 50-day avg
+58.6%
SMA Rs 33.03
vs 200-day avg
+43.8%
SMA Rs 36.44
Beta vs KSE-100

Beta

How hard it swings when the market swings.

How it's worked out

The slope of this stock's daily returns against the KSE-100's, over a year of sessions.

How to read it

1.0 moves with the market, 1.5 exaggerates it by half, below 1 is steadier. It says nothing about direction, only about size.

1.12
correlation 0.53 · 1Y
Volatility

Volatility, 30-day

How jumpy it has been lately, stated per year.

How it's worked out

The standard deviation of the last 30 days of returns, annualised.

How to read it

30% means a typical year's swing of about thirty percent either way. Rising volatility often arrives before news does.

84%
30d · 54% 90d, annualised
Max drawdown · 1Y

Biggest drawdown

The worst peak-to-trough fall of the last year.

How it's worked out

The largest drop from any high to any subsequent low over 250 sessions.

How to read it

The number that tells you whether you could have held it. Most people discover their real risk tolerance somewhere inside this figure.

−53.4%
Volume vs 20-day avg

Volume vs normal

How busy today was against a typical day.

How it's worked out

The latest session's volume divided by the twenty-day average.

How to read it

Above 2 means something happened — an announcement, a block, a rumour. Check the news before reading anything into the price.

8.01×
20-session average 614,116
52-week signal

Position in 52-week range

Where today's price sits between the year's low and high.

How it's worked out

Zero at the 52-week low, 100 at the high.

How to read it

Near 100 is strength or froth; near 0 is a bargain or a falling knife. The number tells you where you are, never which of the two.

Inside range

Figures as of 20 Nov 2026, from daily closes.

09OwnersWho owns the shares

Who holds the shares

Free float
10.0% of sharesas of 6 Nov 2026
Held in the central depository, other than by the government
95.3%as of 30 Nov 2025

Source: SuperX ownership data · free float as of 6 Nov 2026, custody file of 30 Nov 2025.

Dealings by directors and major owners

37 notices in the last 12 months (latest 27 Aug 2026).

  • Purchases by directors and major owners: 17 dealings, 46,500 shares, Rs 1.4 m
  • Sales by directors and major owners: 32 dealings, 121,503 shares, Rs 5.8 m

Net of purchases and sales: -75,003 shares, an estimate of -0.07% of the exchange’s share count on 6 Nov 2026. Gifts and other transfers are left out.

The latest 10 dealings

DateName as printedKindSharesRateSource
15 Jun 2026Kaashif Hussain SiddiqueDirectorSale10,000Rs 40.50notice
17 Apr 2026Kaashif Hussain SiddiqueDirectorSale32,001Rs 42.71notice
6 Mar 2026Kaashif Hussain SiddiqueDirectorPurchase2,000Rs 32.62notice
6 Mar 2026Kaashif Hussain SiddiqueDirectorPurchase2,000Rs 32.61notice
6 Mar 2026Kaashif Hussain SiddiqueDirectorPurchase500Rs 32.60notice
6 Mar 2026Kaashif Hussain SiddiqueDirectorPurchase500Rs 32.60notice
6 Mar 2026Kaashif Hussain SiddiqueDirectorPurchase1,000Rs 32.60notice
6 Mar 2026Kaashif Hussain SiddiqueDirectorPurchase1,000Rs 32.59notice
5 Mar 2026Kaashif Hussain SiddiqueDirectorPurchase5,000Rs 34.50notice
4 Mar 2026Kaashif Hussain SiddiqueDirectorPurchase10,000Rs 31.73notice

The details of 31 notices are not shown yet.

Source: the company’s notices to PSX of dealings in its shares · latest notice

About the company

About Liven Pharma Limited

Liven Pharma Limited was incorporated in Pakistan as a private Limited Company on October 21, 1991 and was converted into a public limited company on April 30, 1992 under the Companies Ordinance, 1984 (Repealed with the enactment of the Companies Act, 2017). The principal activity of the Company is the manufacturing of pharmaceuticals and allied products.

Key people

  • Kashif Hussain Siddiquie · CEO
  • Atif Hussain Siddiqi · Chairman
  • Muhammad Saeed · Company Secretary
Head office
49-Km, Multan Road, Lahore
Auditor
M/s Reanda Haroon Zakaria Aamir Salman Rizwan & Company, Chartered Accountants
Share registrar
F.D. Registrar Services SMC (Pvt.) Ltd., 1705,17th Floor, Saima Trade Tower A, I.I. Chundrigar Road, Karachi
Fiscal year end
June
10Dated record42 dated events

What matters now for LIVEN

A date that matters, as of 20 Nov 2026.

  • Last large move

    20 Nov 2026

    +9.99%

    LIVEN closed up 10.0% at Rs 52.40. That is the most the exchange allows in one day. 3.5 million shares traded, 8.0 times a normal day. LIVEN filed nothing that moves a price, that session or the day before.

The dated record

LIVEN’s dated record

The exchange’s own record and ours: ex-dividends, book closures, results, every session move of 3% or more with the reason written out, the notices that move a price, and the news about Liven Pharma. Dates that have not happened are kept apart from dates that have, and each one says whether it was announced or projected.

The last 90 days · 25

  • 20 Nov 2026

    • Move +9.99% LIVEN closed up 10.0% at Rs 52.40. That is the most the exchange allows in one day. 3.5 million shares traded, 8.0 times a normal day. LIVEN filed nothing that moves a price, that session or the day before.
  • 19 Nov 2026

    • Move +10% LIVEN closed up 10.0% at Rs 47.64. Its sector's typical stock rose 0.3%; the KSE-100 rose 0.3%. So this was LIVEN's own move. That is the most the exchange allows in one day. The whole move came at the open: it opened up 10.0% and closed there.
  • 18 Nov 2026

    • Move -8.67% LIVEN closed down 8.7% at Rs 43.31. Its sector's typical stock fell 0.4%; the KSE-100 fell 0.7%. So this was LIVEN's own move. 3.0 million shares traded, 11.7 times a normal day. LIVEN filed nothing that moves a price, that session or the day before.
  • 17 Nov 2026

    • Move +10% LIVEN closed up 10.0% at Rs 47.42 while the KSE-100 fell 0.4%. Its sector's typical stock fell 0.6%. So this was LIVEN's own move. That is the most the exchange allows in one day. 1.2 million shares traded, 6.4 times a normal day.
  • 16 Nov 2026

    • Move +10% LIVEN closed up 10.0% at Rs 43.11. Its sector's typical stock rose 0.2%; the KSE-100 rose 0.2%. So this was LIVEN's own move. That is the most the exchange allows in one day. The whole move came at the open: it opened up 10.0% and closed there.
  • 13 Nov 2026

    • Move +9.99% LIVEN closed up 10.0% at Rs 39.19. Its sector's typical stock fell 0.2%; the KSE-100 rose 0.3%. So this was LIVEN's own move. That is the most the exchange allows in one day. 591,477 shares traded, 3.9 times a normal day.
  • 12 Nov 2026

    • Move -3.44% LIVEN closed down 3.4% at Rs 35.63. Its sector's typical stock fell 1.0%; the KSE-100 fell 0.9%. So this was LIVEN's own move. It opened flat and fell through the day. 112,911 shares traded, 0.7 times a normal day.
  • 11 Nov 2026

    • Move +6.59% LIVEN closed up 6.6% at Rs 36.90 while the KSE-100 fell 0.1%. Its sector's typical stock fell 0.2%. So this was LIVEN's own move. 1.3 million shares traded, 11.6 times a normal day. LIVEN filed nothing that moves a price, that session or the day before.
  • 10 Nov 2026

    • Move +10.01% LIVEN closed up 10.0% at Rs 34.62. Its sector rose too: 14 of 15 stocks, the typical one by 2.8%. LIVEN beat that by 7.2 points. That is the most the exchange allows in one day. 249,509 shares traded, 2.6 times a normal day.
  • 6 Nov 2026

    • Move -4.35% LIVEN closed down 4.3% at Rs 31.47. Its sector fell too: 13 of 15 stocks, the typical one by 1.3%. LIVEN moved 3.0 points lower than that. 51,636 shares traded, 0.5 times a normal day. LIVEN filed nothing that moves a price, that session or the day before.
  • 5 Nov 2026

    • Move +3.1% LIVEN closed up 3.1% at Rs 32.90. This was a sector day. 13 of 15 PHARMACEUTICALS stocks rose. The typical one rose 2.6%. 866,862 shares traded, 16.4 times a normal day. LIVEN filed nothing that moves a price, that session or the day before.
  • 4 Nov 2026

    • Move +10% LIVEN closed up 10.0% at Rs 31.91. Its sector rose too: 13 of 15 stocks, the typical one by 2.6%. LIVEN beat that by 7.4 points. That is the most the exchange allows in one day. 166,109 shares traded, 3.7 times a normal day.
  • 2 Nov 2026

    • Notice Financial results Financial Results for the Quarter Ended September 30-2026
    • Move -4.54% LIVEN closed down 4.5% at Rs 29.20 while the KSE-100 rose 0.1%. Its sector's typical stock fell 0.9%. So this was LIVEN's own move. 34,892 shares traded, 0.8 times a normal day.

    same day, order not known

  • 27 Oct 2026

    • Notice Board meeting BOARD MEETING FOR 1st Quarter Financials 2027
  • 22 Oct 2026

    • Move -3.97% LIVEN closed down 4.0% at Rs 30.51. Its sector fell too: 14 of 14 stocks, the typical one by 1.5%. LIVEN moved 2.5 points lower than that. 42,859 shares traded, 0.9 times a normal day. LIVEN filed nothing that moves a price, that session or the day before.
  • 14 Oct 2026

    • Results Quarterly results expected between 14 Oct 2026 and 13 Nov 2026 projected A window from past filings, not a date the company gave.
  • 13 Oct 2026

    • Move +3.4% LIVEN closed up 3.4% at Rs 31.02 while the KSE-100 fell 0.2%. Its sector's typical stock rose 0.1%. So this was LIVEN's own move. 414,655 shares traded, 18.2 times a normal day. LIVEN filed nothing that moves a price, that session or the day before.
  • 6 Oct 2026

    • Move +3.33% LIVEN closed up 3.3% at Rs 31.00. This was a sector day. 12 of 14 PHARMACEUTICALS stocks rose. The typical one rose 1.5%. It opened flat and rose through the day. 17,803 shares traded, 0.6 times a normal day.
  • 5 Oct 2026

    • Notice Financial results financial results for the Year Ended June 30, 2026
    • Results Full-year results, to 30 Jun 2026
    • Move -3.66% LIVEN closed down 3.7% at Rs 30.00. This was a sector day. 13 of 14 PHARMACEUTICALS stocks fell. The typical one fell 1.8%. 21,307 shares traded, 0.7 times a normal day.

    same day, order not known

  • 2 Oct 2026

    • Notice Board meeting Board meeting in Progress
  • 25 Sep 2026

    • Notice Board meeting Board Meeting
  • 14 Sep 2026

    • Move -3.37% LIVEN closed down 3.4% at Rs 30.72. This was a sector day. 12 of 14 PHARMACEUTICALS stocks fell. The typical one fell 1.6%. 12,642 shares traded, 0.4 times a normal day. LIVEN filed nothing that moves a price, that session or the day before.

Earlier · 17

Notice 15 notices, 25 Nov 2025 to 29 Apr 2026 open
  • 29 Apr 2026 Financial results Financial Results for the 3rd Quarter Ended 31st March 2026
  • 23 Apr 2026 Board meeting Board Meeting for the 3rd Quarter Financials of 2025-26
  • 27 Feb 2026 Financial results Financial Results for the half year ended December 31, 2025
  • 19 Feb 2026 Board meeting Board Meeting for Accounts for the Period Ended 31st December 2025
  • 7 Jan 2026 Rights issue Credit of Right Shares into CDS account - Liven Pharma Limited
  • 2 Jan 2026 Financial results Financial results for the quarter ended September 30, 2025.
  • 2 Jan 2026 Rights issue No Objection Certificate (NOC) request for release of rights shares subscription money of Liven Pharma Limited
  • 1 Jan 2026 Board meeting Extracts of resolution passed in the board of directors meeting of Liven Pharma Limited - December 30, 2025
  • 26 Dec 2025 Rights issue Right Shares Subscription Status
  • 26 Dec 2025 Board meeting Board meeting for the consideration of Quarterly accounts for the period ended September 30, 2025
  • 22 Dec 2025 Board meeting Board Meeting other than financial results
  • 1 Dec 2025 Rights issue DISPATCH OF LETTER OF RIGHTS AND CDC INTIMATION LETTER
  • 28 Nov 2025 Rights issue LIVEN | Liven Pharma Limited Right Issue Subscription Amount Received From Substantial Shareholders and Directors
  • 27 Nov 2025 Rights issue LIVEN | Liven Pharma Limited Issue Right Shares @ 21.496% at Par Value Rs.10/- Each Per Ordinary Share
  • 25 Nov 2025 Rights issue Notice of Declaration of CDS Eligibility of Letter of Rights (Right Entitlements) of Ordinary Shares of Liven Pharma Limited
Move 2 session moves, 24 Jun 2026 to 14 Jul 2026 open
  • 14 Jul 2026 -5.04% LIVEN closed down 5.0% at Rs 37.13. This was a sector day. 13 of 15 PHARMACEUTICALS stocks fell. The typical one fell 3.6%. 55,558 shares traded, 0.5 times a normal day. LIVEN filed nothing that moves a price, that session or the day before.
  • 24 Jun 2026 +3.54% LIVEN closed up 3.5% at Rs 40.10. Its sector rose too: 13 of 14 stocks, the typical one by 1.0%. LIVEN beat that by 2.5 points. It opened flat and rose through the day. 488,601 shares traded, 3.6 times a normal day.

Showing the most recent session moves and notices. Every ex-dividend, book closure, results filing and ticker change is listed.

Announcements on PSX

What has Liven Pharma announced on PSX?

The latest 5 notices Liven Pharma filed with the exchange, newest first. The title is the exchange’s own text, as filed. The PDF opens at PSX.

  • 12 Nov 2026 · General meeting General Meetings / Briefing Sessions PDF on PSX
  • 12 Nov 2026 · Corporate briefing Notice of Corporate Briefing Session PDF on PSX
  • 02 Nov 2026 · Financial results Financial Results for the Quarter Ended September 30-2026 PDF on PSX
  • 27 Oct 2026 · Board meeting BOARD MEETING FOR 1st Quarter Financials 2027 PDF on PSX
  • 26 Oct 2026 · General meeting Certified True Copy of Resolution Passed in Annual General Meeting Held 26th October 2026 PDF on PSX

From the company’s announcements on the Pakistan Stock Exchange (dps.psx.com.pk), read 21 Nov 2026.

Dates and events on this page are read as of 20 Nov 2026.

11QuestionsQuick answers

LIVEN share price: quick answers

What is the Liven Pharma (LIVEN) share price?

As of 20 Nov 2026, the Liven Pharma (LIVEN) share price is Rs 52.40 (+9.99% on the day). Over the last year it has moved +1.12%.

What is LIVEN's dividend yield?

No trailing dividend yield is shown for Liven Pharma Limited (LIVEN) as of 20 Nov 2026. Check the dividend history table on this page for declared payouts.

How much does LIVEN cost for each rupee it earns?

SuperX cannot price LIVEN against its earnings as of 20 Nov 2026, because the trailing twelve months show no profit to divide by — the earnings are negative or not yet reported. See the financials table for reported earnings per share.

Is LIVEN Shariah compliant?

Yes. PSX lists Liven Pharma Limited (LIVEN) as Shariah-compliant as of 20 Nov 2026 and is included in the KMI All-Share Islamic index. Screening status can change at each review, so confirm with your Shariah advisor before investing.

Is LIVEN trending up or down?

SuperX's trend read for LIVEN is Leaning Up since 17 Nov 2026: see the reasons on this page. Above the 50-day average; Up 54.9% over 3 months; Fell 53.4% from its 1-year peak at worst. The read describes the closes through 20 Nov 2026; it is not a recommendation.

What does LIVEN cost against what it earns?

LIVEN shows a net margin of -29.4%. Whether that price is low or high depends on why the market sets it there, which no ratio answers. A Rs 1,000,000 order is about 145% of a normal session, judged on the median value traded over the last 60 sessions.

What is the total return on LIVEN including dividends?

LIVEN returned +1.1% over the last year counting the cash dividends paid. Dividends are counted as received on their ex-date, not reinvested. Figures to 20 Nov 2026.

How liquid is LIVEN?

On SuperX's reading of the last 60 sessions, a Rs 1,000,000 order moves the price about 93 basis points on a median session, the stock traded on 100% of the last year's sessions. Those are estimates from daily closes and volumes, not from the order book, and they describe normal sessions rather than the one session an order has to clear.

What is LIVEN's beta?

LIVEN's one-year beta against the KSE-100 is 1.12 (correlation 0.53), measured on daily closes to 20 Nov 2026. Its annualised volatility is 84% over 30 days and 54% over 90; the worst peak-to-trough fall in the last year was −53.4%.

Who is the CEO of Liven Pharma?

The CEO of Liven Pharma (LIVEN) is Kashif Hussain Siddiquie (PSX company page, 6 Nov 2026).

Who is the chairperson of Liven Pharma?

The Chairman of Liven Pharma (LIVEN) is Atif Hussain Siddiqi (PSX company page, 6 Nov 2026).

Where is the head office of Liven Pharma?

The head office of Liven Pharma (LIVEN) is at 49-Km, Multan Road, Lahore (PSX company page, 6 Nov 2026).

Who is the auditor of Liven Pharma?

The auditor of Liven Pharma (LIVEN) is M/s Reanda Haroon Zakaria Aamir Salman Rizwan & Company, Chartered Accountants (PSX company page, 6 Nov 2026).

Who is the share registrar of Liven Pharma?

The share registrar of Liven Pharma (LIVEN) is F.D. Registrar Services SMC (Pvt.) Ltd., 1705,17th Floor, Saima Trade Tower A, I.I. Chundrigar Road, Karachi (PSX company page, 6 Nov 2026).

When does the financial year of Liven Pharma end?

The financial year of Liven Pharma (LIVEN) ends in June (PSX company page, 6 Nov 2026).

How many shares of Liven Pharma are outstanding?

Liven Pharma (LIVEN) has 113,040,367 shares outstanding (PSX company page, 6 Nov 2026).

What is the free float of Liven Pharma?

The free float of Liven Pharma (LIVEN) is 10% of its shares (PSX company page, 6 Nov 2026).

Which PSX indices include Liven Pharma?

As of 20 Nov 2026, PSX index data lists Liven Pharma (LIVEN) in the All-Share and KMI All-Share indices.

What does Liven Pharma do?

The company profile on PSX (6 Nov 2026) reads: Liven Pharma Limited was incorporated in Pakistan as a private Limited Company on October 21, 1991 and was converted into a public limited company on April 30, 1992 under the Companies Ordinance, 1984 (Repealed with the enactment of the Companies Act, 2017). The principal activity of the Company is the manufacturing of pharmaceuticals and allied products.

Answers use the facts on this page. Prices are as of 20 Nov 2026.

12SourcesGuides, filings and sources

Guides for LIVEN

Plain explanations of the figures on this page.

Filings and reports

Liven Pharma filings and reports

10 documents Liven Pharma has published — annual reports, quarterly accounts and briefing decks. PSX filings are marked PSX; the rest come from the company’s own investor relations page. Links open the original PDF at the source.

Filings in SuperX Apex

This page has no balance sheet figures for LIVEN. The annual reports are linked below.

Sources and dates

FiguresSourceAs of
ReturnsPSX daily closes, KSE-100 closes20 Nov 2026
DividendsPSX payout notices, bonus and rights records—
ResultsAccounts filed with PSX30 Sep 2026
DealingsThe company’s notices to PSX27 Aug 2026

Each row’s date is the latest one its figures stand at.

Data from PSX via SuperX, delayed and provided for information only — not investment advice. Figures may contain errors; verify with your broker before acting. As of .

Track LIVEN in your portfolio, from 23 December

Trade logging, price alerts and smart-money flows for PSX investors. Join the waitlist and we email once, when it is ready.

SuperX is not a broker and not an adviser. It never places an order and never asks for a broker login.

Get early access, free